Biosimilars [Design Issues]

posted by Kumarnaidu2 – India, 2021-10-22 07:53 (246 d 20:46 ago) – Posting: # 22653
Views: 683

Dear All,

For a medicinal product to be administer as intravenous infusion (for approx. 3 hrs) if we consider Ctrough as one of the primary pk parameter for demonstrating PK similarity, does different rate of infusion amongst enrolled subjects has any impact on Ctrough levels?

Thanks in advance,

Kumar

Complete thread:

UA Flag
Activity
 Admin contact
22,167 posts in 4,645 threads, 1,572 registered users;
online 23 (0 registered, 23 guests [including 3 identified bots]).
Forum time: Sunday 04:40 CEST (Europe/Vienna)

The person interested in success has to learn
to view failure as a healthy, inevitable part
of the process of getting to the top.    Joyce Brothers

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5